71 results about "Cell Cycle Inhibition" patented technology

The invention involves methods of inhibiting the cancer cell cycle to make cancer cells more susceptible to chemotherapeutic agents. In particular, inhibition of CDK4 and / or CDK6 inhibits cell cycle progression in cancer cells. When combined with chemotherapy such cell cycle inhibition can effectively treat even aggressive cancer types that are drug-resistant and intractable to most chemotherapies.

Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

An encased stent that discourages restenosis by having a homogenous endothelial cell lining along the inner wall of the stent. The endothelial cell lining may be coated on the stent before the stent is placed in the artery, or the endothelial cell lining may be grown after placement by several factors that encourage such growth and discourage restenosis. The endothelial cells to coat the stent may be genetically modified to enhance the growth of the endothelial cells into a homogeneous lining. The stent has a continuous lining in the form of a multi-layer polymer coating, including a conducting biocorrosion inhibiting layer and a continuous film of polyurethane coupled by a coupling agent to polyethylene glycol. Various drugs and cell factors may be incorporated into the lining, such as anti-thrombin, anti-inflammatory and anti-coagulant drugs, cell cycle inhibitors, and vascular endothelial growth factors.

The present invention relates to methods for treating cancer comprising utilizing a combination of signal transduction inhibitors. More specifically, the present invention relates to combinations of so called cell cycle inhibitors with mitogen stimulated kinase signal transduction inhibitors, more specifically combinations of CDK inhibitors with mitogen stimulated kinase signal transduction inhibitors, more preferably MEK inhibitors. Other embodiments of the invention relate to additional combinations of the aforesaid combinations with standard anti-cancer agents such as cytotoxic agents, palliatives and antiangiogenics. Most specifically this invention relates to combinations of 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one including salt forms, which is a selective cyclin-dependent kinase 4 (CDK4) inhibitor, in combination with one or more MEK inhibitors, most preferably N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide. The aforementioned combinations are useful for treating inflammation and cell proliferative diseases such as cancer and restenosis.

The present Invention relates to a method of treating abnormal cell growth in a subject, comprising administering to said subject having abnormal cell growth: (a) a compound selected from the group consisting of a camptothecin, a camptothecin derivative, or a pharmaceutically acceptable salt, solvate or prodrug of said compounds; (b) a pyrimidine derivative or a pharmaceutically acceptable salt, solvate or prodrug of said pyrimidine derivative; and (c) an anti-tumor agent selected from the group consisting of antiproliferative agents, kinase inhibitors, angiogenesis inhibitors, growth factor inhibitors, cox-I inhibitors, cox-II inhibitors, mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, radiation, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, antibodies, cytotoxics, anti-hormones, anti-androgens and combinations thereof.

Disclosed herein are therapeutic devices, compositions and methods for treating proliferative diseases. For example, within one aspect of the invention therapeutic devices are provided, comprising a device that locally administers radiation and a cell-cycle inhibitor

The carbazolyl alkaloid medicine is used as cell cycle inhibitor, cell death inducer or anticarcinogen. It is discovered 29 kinds of carbazolyl alkaloid derivatives or salt separated from black-fruit Chinese wampee may be used in preparing cell cycle inhibitor, cell death inducer or anticarcinogen. The preparation of the carbazolyl alkaloid medicine includes extraction of dry bark, branch or leaf of black-fruit Chinese wampee with ethanol or its water solution to obtain coarse extraction, organic extraction of the coarse extraction, repeated column extraction, silica gel extraction, repeated HPLC preparation, recrystallization to separate the derivatives, mixing with medicinal supplementary material.

The present invention relates to indole carbazole alkaloid and its preparation process and use. The present invention adopts Actinomadura sp.007 from ocean in fermentation to prepare indole carbazole alkaloid compound with novel chemical structure. Test shows that the indole carbazole alkaloid compound may be used as cell period inhibitor, tumor cell proliferation inhibitor and antitumor preparation.

The invention discloses a preparation method of 2,3-indolediketone-3-oxime or isatin-3-oxime and discloses application of the 2,3-indolediketone-3-oxime in preparing cancer prevention or control drugs. The application of the 2,3-indolediketone-3-oxime in prevention and control of cancer or other malignant tumours is characterized in that the substance has obvious growth inhibition action on various tumour cells, has specific G1-phase blocking action on cell generation cycle, i.e. the substance can stop the tumour cells carrying out DNA (deoxyribonucleic acid) replication, and has obvious down regulation action on the expression of cycle proteins cyclin E, cyclin B and cyclin A, obvious up regulation action on the expression of a cell cycle inhibiting factor p21, induction action on cancer cells or precancerosis cells and sensitization action on gene toxic chemotherapeutic agents.

The present invention provides a method for imaging a disease or condition in a mammal which includes the steps of; administering a therapeutically effective amount of a cell cycle inhibitor to effectively stop proliferation of eukaryotic cells at a cell cycle checkpoint between the G1 and S phase, stopping administration of the cell cycle inhibitor for a period of time, administering a marker to the mammal and imaging the mammal.

The invention relates to the technical field of medical treatment. The tea double-chlorine carboxamide and tea double-bromine carboxamide are newly synthesized compounds which can inhibit growths and invasions of cancer cells such as lung cancer, breast cancer, liver cancer, stomach cancer, colon cancer, prostate cancer, pancreatic cancer, cervical cancer, lymphoma, leukemia, and melanoma, and can obviously inhibit the tumor growth and metastasis in the body, and the inhibition effect of the compound is better than that of an anticancer medicament; the mechanism of action involves a receptor which is closely related to down-regulation and inhibition of the growth, invasion and metastasis of a tumor, signal transduction and regulation protein and kinase levels and a binding of a nuclear factor and DNA (Deoxyribonucleic Acid), and up-regulation of factors such as tumor suppressor proteins and cell cycle inhibitor proteins simultaneously; double tea chlorine carboxamide and double tea chlorine carboxamide can directly inhibit activities of histone deacetylase and histone methyltransferase EZH2(Enhancer Of Zeste Homolog 2) and the binding of the inflammatory factor NF-kB and DNA, and the activities of tea double-chlorine carboxamide and tea double-bromine carboxamide are better than that of the clinical anti-cancer medicament. The invention provides new applications of tea double-chlorine carboxamide and tea double-bromine carboxamide and intermediate compounds in preventing and treating the diseases such as cancers, inflammation, cardiovascular and immune deficiencies.

The invention relates to the technical field of medical treatment. Theanine nitrate aromatic amide is a newly synthetic compound, can inhibit the growth and invasion of such cancer cells as human lung cancer, breast cancer, liver cancer, gastric cancer, colon cancer, prostate cancer, pancreatic cancer, cervical cancer, lymphoma, leukemia and melanoma or the like, and can significantly inhibit tumor growth and metastasis in vivo, and the inhibitory effect of the theanine nitrate aromatic amide exceeds that of anticancer drugs; the action mechanism involves down-regulation of receptors closely related to inhibition of tumor growth, invasion and metastasis, regulation and control of protein and kinase levels and combination of a nuclear factor with DNA by signal transduction, and up-regulation of such factors as cancer suppressor protein and cell cycle inhibitory protein factor or the like; the theanine nitrate aromatic amide can directly inhibit the activity of histone deacetylase and histone methyltransferase EZH2 and the combination of an inflammatory factor NF-kappa B and DNA, and the activity of the nitrate fluorine aromatic amide exceeds that of the anticancer drugs. The invention provides a new use of the theanine nitrate aromatic amide in prevention and treatment of such diseases as tumor, inflammation, cardiovascular and cerebrovascular diseases and immunodeficiency, etc.

The invention relates to the field of medical technology. Ethyl 6-bromocoumarin-3-carboxylyl L-theanine, a novel synthetic compound, can inhibit the growth and invasion of cancer cells of human lung cancer, breast cancer, liver cancer, gastric cancer, colon cancer, prostatic cancer, pancreatic cancer, cervical cancer, lymphadenoma, leucocythemia, melanoma, and the like, and can remarkably inhibit the growth and metastasis of the tumors in a body, with an inhibiting effect exceeding the inhibiting effects of anti-cancer drugs. The mechanism of action involves the down regulation inhibition of the bonding of the receptors which are closely related to growth, invasion and metastasis of the tumors, signal transduction regulation and control proteins, the kinase level and a nuclear factor with DNA, and also upper regulation of factors such as cancer-inhibiting proteins and cell cycle inhibition proteins. The ethyl 6-bromocoumarin-3-carboxylyl L-theanine can directly inhibit the activity of histone deacetylase, the activity of histonemethylferase EZH2, and combination of a inflammatory factor NF-[Kabba]B and DNA. The activity of the ethyl 6-bromocoumarin-3-carboxylyl L-theanine exceeds the activity of the anti-cancer drugs. The invention provides new applications of the ethyl 6-bromocoumarin-3-carboxylyl L-theanine for prevention and treatment of diseases such as tumors, inflammation, heart and cerebral vessels and immunodeficiency.

The invention relates to cyclohexenone bicyclo (condensed ring) compound containing one long chain hydrocarbon represented by formula I, extracts containing these compounds, the process for preparing these compounds and extracts and their use (the definitions of R1-R4 in the formula I are disclosed in the specification. The cyclohexenone bicyclo (condensed ring) compounds can be used as cell cycle inhibitors, cell apoptosis inducers, cell propagation inhibitors, and antineoplastic agents.

The invention relates to a pterocarya stenoptera extract, its preparation and use, wherein a novel compound of diphenyl epoxy heptane is extracted from Tokyo pterocarya stenoptera. Experiment has proved that the compound can be used as cell cycle depressor, cell apoptosis inducer or antineoplastic agent.

The invention discloses an amino acid sequence with a characteristic of bonding histone deacetylase 1 and an expression vector thereof, which belongs to the field of biotechnology. The amino acid is conservative in sequential evolution and has the characteristic of special bonding histone deacetylase 1. After an expression vector pcDNA3-FATS constructed by the amino acid sequence undergoes cell transfection, the expression level of periodical inhibitory protein p21 of a specific induced cell is improved; and the combination of the bonding histone deacetylase 1 and the p21 is restrained to increase the acetylation modification of the p21 protein and restrain degradation of the p21 protein. The amino acid sequence and the expression vector thereof prove the anti-cancer effect of a small molecular compound of inhibition histone deacetylase applied to a clinical experiment and provide a natural simulation target spot for the research and development of a new-generation more specific anti-HDAC1 chemical medicament.

Pump contacting with tissue, sensor and scar formation preventing agent are combined in use to prevent scar from forming. Otherwise, while all the pump and sensor are implanted into an animal body, scar is possible to be formed.

The invention relates to the field of medical technology. Ethyl 6-chlorocoumarin-3-carboxylyl L-theanine, a novel synthetic compound, can inhibit the growth and invasion of cancer cells of human lung cancer, breast cancer, liver cancer, gastric cancer, colon cancer, prostatic cancer, pancreatic cancer, cervical cancer, lymphadenoma, leucocythemia, melanoma, and the like, and can remarkably inhibit the growth and metastasis of the tumors in a body, with an inhibiting effect exceeding the inhibiting effects of anti-cancer drugs. The mechanism of action involves the down regulation inhibition of the bonding of the receptors which are closely related to growth, invasion and metastasis of the tumors, signal transduction regulation and control proteins, the kinase level and a nuclear factor with DNA, and also upper regulation of factors such as cancer-inhibiting proteins and cell cycle inhibition proteins. The ethyl 6-chlorocoumarin-3-carboxylyl L-theanine can directly inhibit the activity of histone deacetylase, the activity of histonemethylferase EZH2, and combination of a inflammatory factor NF-[Kabba]B and DNA. The activity of the ethyl 6-chlorocoumarin-3-carboxylyl L-theanine exceeds the activity of clinical anti-cancer drugs. The invention provides new applications of the ethyl 6-chlorocoumarin-3-carboxylyl L-theanine in prevention and treatment of diseases such as tumors, inflammation, heart and cerebral vessels and immunodeficiency.

Methods of modulating the properties of a cell culture expressing a protein of interest are provided. In various embodiments the methods relate to the addition of cell cycle inhibitors to growing cell cultures.

The invention relates to the field of medical technology. Ethyl coumarin-3-carboxylyl L-theanine, a novel synthetic compound, can inhibit the growth and invasion of cancer cells of human lung cancer, breast cancer, liver cancer, gastric cancer, colon cancer, prostatic cancer, pancreatic cancer, cervical cancer, lymphadenoma, leucocythemia, melanoma, and the like, and can remarkably inhibit the growth and metastasis of the tumors in a body, with an inhibiting effect exceeding the inhibiting effects of anti-cancer drugs. The mechanism of action involves the down regulation of receptors which are closely related to growth inhibition, invasion inhibition and metastasis inhibition of tumors, signal transduction regulation and control proteins, the kinase level and combination of a nuclear factor and DNA, and also upper regulation of factors such as cancer-inhibiting proteins and cell cycle inhibition proteins. The ethyl coumarin-3-carboxylyl L-theanine can directly inhibit the activity of histone deacetylase, the activity of histonemethylferase EZH2, and combination of a inflammatory factor NF-[Kabba]B and DNA. The activity of the ethyl coumarin-3-carboxylyl L-theanine exceeds the activity of the anti-cancer drugs. The invention provides new applications of the ethyl coumarin-3-carboxylyl L-theanine in prevention and treatment of disease such as tumors, inflammation, heart and cerebral vessels and immunodeficiency.

Methods of modulating the properties of a cell culture expressing a protein of interest are provided. In various embodiments the methods relate to the addition of cell cycle inhibitors to growing cell cultures.

The present invention provides a series of cyclin-dependent protein kinases (Cdks) inhibitors, Scutellaria flavonoid organic amine derivatives, synthesis and use thereof. The preparation method is as follows: taking Baicalein (or Wogonin) from Scutellaria baicalensis as lead compound, mixting it with formaldehyde solution and organic amine compounds based on the molar ratio of 1:1-1.2:1-1.2, adding methanol of duplicate weight than baicalein and reacting at 50-70° C., filtering the sediment and washing and then drying so as to get the product with a content of not less than 97% (weight). Similar to Flavopiridol and P276-00, the activity of baicalein organic amine derivatives inhibiting Cdks has an increase of 50 times compared with that of Baicalin. It can selectively induce apoptosis of the proliferative phase cancer cells, which has scarcely any influence to the normal structure, and it belongs to anticancer drugs of cell cycle inhibitor kind. The product has a rich source of raw materials and has simple process, high purity, low cost, clear metabolic mechanism, high efficiency and low toxicity, which can be made into oral preparations or injections together with acid salts and is expected to become high efficient and low toxicity anti-cancer and AIDS drugs.

The invention discloses an aromatic geldanamycin derivant, making method, drug composition and application with chemical structure I, wherein R1-R8 is defined as request; the composition can prepare periodical inhibitor and tumour proof agent of cell.

The present invention relates to geldanamycin type carbonyl radical added benzoquinone derivative and its preparation process as well as the medicine composition with the compound as active component and its use. The compound is prepared through fermentation with, say, pseudostreptoverticillium, and it is proved experimentally that the compound may be used in preparing cell period inhibitor and antitumor preparation.

A diphenyl-ether compound, its production and use are disclosed. The process is carried out by separating from marine sampler to obtain aspergillus-B-F-2(Aspergillus sp.B-F-2) and producing the final product. It can be used as cell periodic inhibitor, cell multiplication inhibitor and antineoplastic preparation.

The present invention provides a series of cyclin-dependent protein kinases (Cdks) inhibitors, Scutellaria flavonoid organic amine derivatives, synthesis and use thereof. The preparation method is as follows: taking Baicalein (or Wogonin) from Scutellaria baicalensis as lead compound, mixting it with formaldehyde solution and organic amine compounds based on the molar ratio of 1:1-1.2:1-1.2, adding methanol of duplicate weight than baicalein and reacting at 50-70° C., filtering the sediment and washing and then drying so as to get the product with a content of not less than 97% (weight). Similar to Flavopiridol and P276-00, the activity of baicalein organic amine derivatives inhibiting Cdks has an increase of 50 times compared with that of Baicalin. It can selectively induce apoptosis of the proliferative phase cancer cells, which has scarcely any influence to the normal structure, and it belongs to anticancer drugs of cell cycle inhibitor kind. The product has a rich source of raw materials and has simple process, high purity, low cost, clear metabolic mechanism, high efficiency and low toxicity, which can be made into oral preparations or injections together with acid salts and is expected to become high efficient and low toxicity anti-cancer and AIDS drugs.